Category: Curacle

PharmaShots Weekly Snapshots (October 25 – 29, 2021)

ADC Reports EMA’s Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma Published: 29 Oct, 2021 | Tags: ADC, EMA, MAA, Zynlonta, R/R Diffuse Large B-Cell Lymphoma Impact Receives US FDA’s IND Clearance for IMP9064 to Treat Solid Tumor Published: 29 Oct, 2021 | Tags: Impact, US, FDA, IND, IMP9064, Solid Tumor […]

Curacle Signs a License and Collaboration Agreement with Théa for Development and Commercialization of CU06-RE to treat Diabetic Macular Edema and Wet-AMD

Shots: Curacle to receive a total of ~$2B including $6M up front & is eligible to receive ~$157.5M as development, regulatory and sales milestones along with royalties on sales upon the successful development of CU06-RE. The companies will closely collaborate on the clinical development of the product Curacle will hold the marketing rights in all […]